RPB researchers are working to understand and prevent macular degeneration, to halt its progression, and to develop optical devices to offset vision loss.
The model will allow researchers to better assess treatments for this hard-to-study cause of blindness.
The findings may have significant therapeutic implications for AMD, the most common cause of elderly blindness in the developed world
At the ARVO Inaugural Press Conference, three RPB-funded scientists pushing the boundaries of imaging, early detection, regeneration.
Adults whose eyes are slow to adjust to the dark have a greater risk of developing age-related macular degeneration.
Some patients taking high doses of a cholesterol-lowering medication had complete resolution of lipid deposits in the dry form of age-related macular degeneration (AMD).
RPB-supported researchers have made a significant discovery that might lead to the delay or prevention of the most common cause of blindness in the elderly.
|General Info||Research Scientists & Grantees||Eye Care Specialists||Donors & Partners|